KLARIA PHARMA HOLDING AB
Research KLARIA PHARMA HOLDING AB (6FN) on Bullrun: market cap EUR 16.63M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6FN
- ExchangeF
- CountrySweden
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Market capEUR 16.63M
- Financial periodQ4 2025
- Net income-EUR 8.44M
- Free cash flow-EUR 2.42M
Valuation Snapshot
latest market cap is EUR 16.63M.
About KLARIA PHARMA HOLDING AB
Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction. The company also offers Sirolimus which is in pre-clinical stage for prevention of organ transplant rejection.
Frequently asked questions
What is KLARIA PHARMA HOLDING AB's market cap?
KLARIA PHARMA HOLDING AB's market capitalization is EUR 16.63M.
What does KLARIA PHARMA HOLDING AB do?
Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval;